Literature DB >> 17077345

Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats.

Amanda Martins Baviera1, Neusa Maria Zanon, Luiz Carlos Carvalho Navegantes, Renato Hélios Migliorini, Isis do Carmo Kettelhut.   

Abstract

Previous studies from this laboratory have shown that catecholamines exert an inhibitory effect on muscle protein degradation through a pathway involving the cAMP cascade. The present work investigated the systemic effect of pentoxifylline (PTX; cAMP-phosphodiesterase inhibitor) treatment on the rate of overall proteolysis, the activity of proteolytic systems, and the process of protein synthesis in extensor digitorum longus muscles from normal and acutely diabetic rats. The direct in vitro effect of this drug on the rates of muscle protein degradation was also investigated. Muscles from diabetic rats treated with PTX showed an increase (22%) in the cAMP content and reduction in total rates of protein breakdown and in activity of Ca2+-dependent (47%) and ATP proteasome-dependent (23%) proteolytic pathways. The high content of m-calpain observed in muscles from diabetic rats was abolished by PTX treatment. The addition of PTX (10(-3) M) to the incubation medium increased the cAMP content in muscles from normal (22%) and diabetic (51%) rats and induced a reduction in the rates of overall proteolysis that was accompanied by decreased activity of the Ca2+-dependent and ATP proteasome-dependent proteolytic systems, in both groups. The in vitro addition of H-89, an inhibitor of protein kinase A (PKA), completely blocked the effect of PTX on the reduction of proteolysis in muscles from normal and diabetic rats. The present data suggest that PTX exerts a direct inhibitory effect on protein degradative systems in muscles from acutely diabetic rats, probably involving the participation of cAMP intracellular pathways and activation of PKA, independently of tumor necrosis factor-alpha inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077345     DOI: 10.1152/ajpendo.00147.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

Review 1.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 2.  Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.

Authors:  Liliane Tetsi; Anne-Laure Charles; Stéphanie Paradis; Anne Lejay; Samy Talha; Bernard Geny; Claire Lugnier
Journal:  Cell Mol Life Sci       Date:  2016-12-30       Impact factor: 9.261

Review 3.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

4.  Sex-related differences in the effects of high-fat diets on DHEA-treated rats.

Authors:  Ana Lúcia Cecconello; Marcia Trapp; Ana Lúcia Hoefel; Cláudia Vieira Marques; Bruno Dutra Arbo; Gabriela Osterkamp; Luiz Carlos Rios Kucharski; Maria Flávia Marques Ribeiro
Journal:  Endocrine       Date:  2014-10-10       Impact factor: 3.633

Review 5.  Muscle wasting in disease: molecular mechanisms and promising therapies.

Authors:  Shenhav Cohen; James A Nathan; Alfred L Goldberg
Journal:  Nat Rev Drug Discov       Date:  2015-01       Impact factor: 84.694

Review 6.  Alterations of cAMP-dependent signaling in dystrophic skeletal muscle.

Authors:  Rüdiger Rudolf; Muzamil M Khan; Danilo Lustrino; Siegfried Labeit; Isis C Kettelhut; Luiz C C Navegantes
Journal:  Front Physiol       Date:  2013-10-17       Impact factor: 4.566

7.  Urocortin 2 promotes hypertrophy and enhances skeletal muscle function through cAMP and insulin/IGF-1 signaling pathways.

Authors:  Natalia Lautherbach; Dawit A P Gonçalves; Wilian A Silveira; Sílvia Paula-Gomes; Rafael Rossi Valentim; Neusa M Zanon; Marcelo G Pereira; Elen H Miyabara; Luiz C C Navegantes; Isis C Kettelhut
Journal:  Mol Metab       Date:  2022-04-04       Impact factor: 8.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.